A Pordenone c'è Arsenale Bioyards, una startup che vuole ridurre i costi di un processo per ottenere da lieviti e funghi alternative bio al petrolchimico

L’azienda di Pordenone ha appena concluso un aumento di capitale per 10 milioni di euro, guidato da Cdp. Con la sua piattaforma end to end riprogramma geneticamente batteri e lieviti per trasformarli in strumenti di produzione di insulina, lattoferrina, collegene.

Arsenale Bioyards, azienda che vuole trasformare il mercate del bio-manufacturing, ha annunciato la chiusura del suo primo round di investimento seed da 10 milioni di euro

On August 9th, 2023, the synthetic biology pioneer Amyris announced its voluntary filing for Chapter 11/Bankruptcy. I think this is a very important moment for the industry as it officially sanctions the end of an era, and (I hope) the beginning of a new one for the industry, and more in general for the transition of our industrial backbone from an exploitative to generative paradigm.

Not so long ago, the technology startup landscape in Europe was sparsely populated, especially when compared with other tech-rich regions of the world.

Corporates are sitting on a wealth of resources (not only financial) that could help European deeptech companies scale

There’s another industrial revolution forming, and it promises to be at least as far reaching as the ones before it.

Leaders will need to be resilient, open-minded, and creative. Poetry can show them the way.

Typically developed by startups (often university spinoffs), deep technologies are notable for their novelty and potential impact, for the time and scale needed to develop them, and for the level of financing required to move from laboratory science to viable commercial product.

It is nothing new that fundamental diversity is beneficial, economically and socially.